Praxis Precision Medicines

CompanyUnited States

Praxis Precision Medicines develops one asset, in phase 3 (ulixacaltamide in essential tremor). Mostly small molecule acting on CACNA1G, CACNA1H and CACNA1I; based in the United States.

1
Asset
Furthest: Phase 3; 1
Trial: 0
Signals

Pipeline

1

ulixacaltamide
T-type calcium channel blocker
Phase 3, Small molecule, CACNA1G, CACNA1H, essential tremor

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Trials1
Similar companies2

Updated 8 Oct 2026 · 4 sources